Odyssey Health, Inc.
Close on Oct 19, 2026
- Market cap
- $1.25M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Odyssey Health has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Odyssey Health filed with the SEC
Inc. Secures Exclusive Global Distribution Rights for BreastCheck™ to Drive Recurring Revenue Growth
Material agreement · Other events · EX-99.1 to Form 8-K
Odyssey Health, Inc. Secures Multi-Million-Dollar,
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Odyssey Health, Inc., Enters the $26 Billion
Material agreement · Other events · EX-99.1 to Form 8-K
Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
Material agreement · Other events · EX-99.1 to Form 8-K
announces letter of intent to merge with public company, Odyssey Health Inc.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Odyssey Health, Inc. Provides Update on Company
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
Material agreement · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Health Inc. Files Full US Patent Application on
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Statement Regarding its Concussion Drug Development Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Successful Completion of Phase I Clinical Trial for Concussion Drug
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Odyssey Health Achieves Positive Safety Outcomes
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Odyssey Group International Receives Donation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Odyssey Group International Files Patent On Novel Breath-Propelled
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K